Effects of Denosumab on the Geometry of the Proximal Femur in Postmenopausal Women in Comparison with Alendronate

Journal of Clinical Densitometry

Volumn 11, Issue 3, 2008, Pages 351-359

  Beck, Thomas J ^a   Michael Lewiecki, E ^b   Miller, Paul D ^c   Felsenberg, Dieter ^d   Liu, Yu ^e   Ding, Beiying ^e   Libanati, Cesar ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^c University of Colorado Health Sciences Center   (United States)

^d HUMBOLDT UNIVERSITY   (Germany)

^e AMGEN INC   (United States)

Author keywords

Bone geometry; denosumab; hip; osteoporosis; proximal femur; RANKL inhibitor

Indexed keywords

ALENDRONIC ACID; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO;

ADULT; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; HUMAN; MAJOR CLINICAL STUDY; OSTEOLYSIS; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ABSORPTIOMETRY, PHOTON; ALENDRONATE; ANTIBODIES, MONOCLONAL; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; FEMUR; HUMANS; LEAST-SQUARES ANALYSIS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RANK LIGAND; TREATMENT OUTCOME;

EID: 50849103641     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocd.2008.04.001     Document Type: Article

References (36)

1. Bonnick S.L., and Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med 119 4A (2006) 25S-31S
2. Miller P.D. Monitoring osteoporosis therapies. Curr Osteoporos Rep 5 1 (2007) 38-43
3. Cummings S.R., and Black D. Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med 98 2A (1995) 24S-28S
4. Delmas P.D., Li Z., and Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 19 2 (2004) 330-337
5. Beck T. Measuring the structural strength of bones with dual-energy X-ray absorptiometry: principles, technical limitations, and future possibilities. Osteoporos Int 14 Suppl (2003) 581-588
6. Beck T.J., Looker A.C., Ruff C.B., et al. Structural trends in the aging of femoral neck and proximal shaft: analysis of the Third National Health and Nutrition Examination Survey duel energy X-ray absorptiometry data. J Bone Miner Res 15 12 (2000) 2297-2304
7. Rivadeneira F., Zillikens M.C., De Laet C.E.D.H., et al. Femoral neck BMD is a strong predictor of hip fracture susceptibility in elderly men and women because it detects cortical bone instability: the Rotterdam Study. J Bone Miner Res 22 11 (2007) 1781-1790
8. Greenspan S.L., Beck T.J., Resnick N.M., et al. Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. J Bone Miner Res 20 9 (2005) 1525-1532
9. Uusi-Rasi K., Beck T.J., Semanick L.M., et al. Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. Osteoporos Int 17 4 (2006) 575-586
10. Uusi-Rasi K., Semanick L.M., Zanchetta J.R., et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 36 6 (2005) 948-958
11. Burgess T.L., Qian Y., Kaufman S., et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145 3 (1999) 527-538
12. Hsu H., Lacey D.L., Dunstan C.R., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 96 7 (1999) 3540-3545
13. Lacey D.L., Tan H.L., Lu J., et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157 2 (2000) 435-448
14. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 2 (1998) 165-176
15. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95 7 (1998) 3597-3602
16. Lewiecki E.M., Miller P.D., McClung M.R., et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res 22 12 (2007) 1832-1841
17. McClung M.R., Lewiecki E.M., Cohen S.B., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354 8 (2006) 821-831
18. Martin R.B., and Burr D.B. Non-invasive measurement of long bone cross-sectional moment of inertia by photon absorptiometry. J Biomech 17 3 (1984) 195-201
19. Beck T.J., Looker A.C., Ruff C.B., et al. Structural trends in the aging femoral neck and proximal shaft: analysis of the Third National Health and Nutrition Examination Survey dual-energy X-ray absorptiometry data. J Bone Miner Res 15 12 (2000) 2297-2304
20. Khoo B.C., Beck T.J., Qiao Q.H., et al. In vivo short-term precision of hip structure analysis variables in comparison with bone mineral density using paired dual-energy X-ray absorptiometry scans from multi-center clinical trials. Bone 37 1 (2005) 112-121
21. Armitage P., and Colton T. Encyclopedia of Biostatistics. 2nd ed. (2005), John Wiley and Sons, Ltd, Chichester, UK
22. Melton III L.J., Crowson C.S., and O'Fallon W.M. Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporosis Int 9 1 (1999) 29-37
23. Stone K.L., Seeley D.G., Lui L.Y., et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 18 11 (2003) 1947-1954
24. Mackey D.C., Lui L.-Y., Cawthon P.M., et al. High-trauma fractures and low bone mineral density in older women and men. JAMA 298 20 (2007) 2381-2388
25. Kostenuik P.J., Warmington K., Grisanti M., et al. RANKL inhibition with AMG 162, a fully human MAb, causes sustained suppression of bone resorption and increased BMD in knockin mice expressing humanized RANKL. J Bone Miner Res 20 Suppl1 (2005) S259
26. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18 2 (1996) 75-85
27. Rodan G., Reszka A., Golub E., and Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 20 8 (2004) 1291-1300
28. Sato M., Grasser W., Endo N., et al. Bisphosphonate action. J Clin Invest 88 (1991) 2095-2105
29. Young W. Elastic stability formulas for stress and strain. Roark's formulas for stress and strain. 6th ed. (1989), McGraw-Hill, New York 688
30. Mayhew P.M., Thomas C.D., Clement J.G., et al. Relation between age, femoral neck cortical stability, and hip fracture risk. [see comment]. Lancet 366 9480 (2005) 129-135
31. Bell K.L., Loveridge N., Power J., et al. Structure of the femoral neck in hip fracture: cortical bone loss in the inferoanterior to superoposterior axis. J Bone Miner Res 14 1 (1999) 111-119
32. Hillier T., Beck T., Oreskovic T., et al. Predicting long term hip fracture risk with bone mineral density and hip structure in post-menopausal women: the Study of Osteoporotic Fractures (SOF). J Bone Miner Res 18 Suppl2 (2003) S21
33. Beck T.J., Oreskovic T.L., Stone K.L., et al. Structural adaptation to changing skeletal load in the progression toward hip fragility: the study of osteoporotic fractures. J Bone Miner Res 16 6 (2001) 1108-1119
34. Beck T.J. Extending DXA beyond bone mineral density: understanding hip structure analysis. Curr Osteoporos Rep 5 2 (2007) 49-55
35. Hangartner T.N. Thresholding technique for accurate analysis of density and geometry in QCT, pQCT and microCT images. J Musculoskelet Neuronal Interact 7 1 (2007) 9-16
36. Beck T., Brown J., Gustafsson S., et al. In vivo comparison of CT and DXA methods of proximal femur cross-sectional geometry measuement using HSA. J Bone Miner Res 22 Suppl 1 (2007) 418-419